Monthly Archive:: February 2017

FDA Expands Indication for Revlimid (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)

SUMMIT, N.J.–(BUSINESS WIRE) February 22,2017 — Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for Revlimid (lenalidomide) 10 mg capsules to include use for patients with multiple myeloma as maintenance …

The Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous Antibiotic Carbavance (meropenem-vaborbactam)

Treatment for Urinary Tract Infection The Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous Antibiotic Carbavance (meropenem-vaborbactam) PARSIPPANY, N.J.–(BUSINESS WIRE)–Feb. 21, 2017– The Medicines Company (NASDAQ:MDCO) today announced that the U.S. Food and Drug Administration (FDA) …